[1] Jemal A, Muray T, Ward E, et al. Cancer statistics, 2005[J]. CA Cancer J Clin, 2005, 55(1): 10-30.
[2] Bruix J, Sherman M. Management of hepatocellular carcinoma[J]. Hepatology, 2005, 42(5): 1208-1236.
[3] European association for the study of the liver. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2012, 56(4): 908-943.
[4] 叶胜龙, 秦叔逵, 吴孟超, 等. 原发性肝癌规范化诊治的专家共识[J]. 临床肝胆病杂志, 2009, 25(2): 83-92.
[5] Kudo M, Izumi N, Kokudo N, et al. Management of hepa tocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Heatology (JSH) 2010 updated version[J]. Dig Dis, 2011, 29 (3): 339-364.
[6] Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the Study of the Liver consensus recommenda tions on hepatocellular carcinoma[J]. Hepatol Int, 2010, 4(2): 439-474.
[7] Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4): 378-390.
[8] Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised,double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1): 25-34.
[9] Torzilli G, Belghiti J, Kokudo N, et al. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to theEASL/AASLD recommendations?: an observational study of the HCC East-West study group[J]. Ann Surg, 2013, 257 (5): 929-937.
[10] Zhong JH, Ke Y, Gong WF, et al. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma[J]. Ann Surg, 2014, 260 (2): 329-340.
[11] Wang JH, Changchien CS, Hu TH, et al. The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma-Survival analysis of 3892 patients[J]. Eur J Cancer, 2008, 44(7): 1000-1006.
[12] Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma[J]. J Hepatol, 2004, 41(5): 864-880.
[13] Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial[J]. J Hepatol, 2012, 57 (4): 821-829.
[14] Iavarone M, Cabibbo G, Piscaglia F, et al. Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy[J]. Hepatology, 2011, 54(6): 2055-2063.
[15] Wang SN, Chuang SC, Lee KT. Efficacy of sorafenib as ad juvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery: a pilot study[J]. Hepatol Res, 2014, 44(5): 523-531.
[16] 庄磊, 魏永刚, 杨家印, 等. 中晚期肝细胞肝癌术后行索拉非尼治疗的疗效分析[J]. 中国普通外科杂志, 2014, 23 (7): 882-886.
